CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 45 enrolled
Drug / intervention
Vismodegib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01267955
NCT01267955Phase 2Active
CompareCT.gov

A Phase 2 Study of GDC-0449 in Patients With Advanced Chondrosarcomas

National Cancer Institute (NCI)·interventional·Posted Dec 29, 2010·Updated Apr 13, 2026

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Pharmacogenomic Study, and 1 other intervention for Clear Cell Chondrosarcoma and 6 related conditions. Active but no longer recruiting, targeting 45 participants across 6 sites.

Detailed Summary

This phase II trial studies how well vismodegib works in treating patients with chondrosarcomas that have spread to other places in the body and usually cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as vismodegib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClear Cell Chondrosarcoma, Dedifferentiated Chondrosarcoma, Locally Advanced Chondrosarcoma, Mesenchymal Chondrosarcoma, Metastatic Chondrosarcoma, Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
CountriesFrance
Collaborators--

Timeline

Phase 2Active
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 29, 2010
Enrollment StartDec 21, 2010
Primary CompletionJun 30, 2018
Study CompletionJul 21, 2026
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 15.5 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Pharmacogenomic Studyother

Correlative studies

Vismodegibdrug

Given PO